| Literature DB >> 31024862 |
Pedro Curto1,2,3,4, Sean P Riley4, Isaura Simões3,4, Juan J Martinez4.
Abstract
Despite their high degree of genomic similarity, different spotted fever group (SFG) Rickettsia are often associated with very different clinical presentations. For example, Rickettsia conorii causes Mediterranean spotted fever, a life-threatening disease for humans, whereas Rickettsia montanensis is associated with limited or no pathogenicity to humans. However, the molecular basis responsible for the different pathogenicity attributes are still not understood. Although killing microbes is a critical function of macrophages, the ability to survive and/or proliferate within phagocytic cells seems to be a phenotypic feature of several intracellular pathogens. We have previously shown that R. conorii and R. montanensis exhibit different intracellular fates within macrophage-like cells. By evaluating early macrophage responses upon insult with each of these rickettsial species, herein we demonstrate that infection with R. conorii results in a profound reprogramming of host gene expression profiles. Transcriptional programs generated upon infection with this pathogenic bacteria point toward a sophisticated ability to evade innate immune signals, by modulating the expression of several anti-inflammatory molecules. Moreover, R. conorii induce the expression of several pro-survival genes, which may result in the ability to prolong host cell survival, thus protecting its replicative niche. Remarkably, R. conorii-infection promoted a robust modulation of different transcription factors, suggesting that an early manipulation of the host gene expression machinery may be key to R. conorii proliferation in THP-1 macrophages. This work provides new insights into the early molecular processes hijacked by a pathogenic SFG Rickettsia to establish a replicative niche in macrophages, opening several avenues of research in host-rickettsiae interactions.Entities:
Keywords: Rickettsia conorii; Rickettsia montanensis; host-pathogen interactions; macrophages; spotted fever group Rickettsia; transcriptional profiling
Mesh:
Year: 2019 PMID: 31024862 PMCID: PMC6467950 DOI: 10.3389/fcimb.2019.00097
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1SFG Rickettsia trigger reprogramming in THP-1 macrophages early in infection. (A,B) Volcano plots of log2 fold change ratio of the expression levels in R. conorii- (A) and R. montanensis- (B) infected THP-1 macrophages over that in uninfected cells plotted against the -log10 (q-value). Statistically differentially expressed genes found in increased abundance and in decreased abundance are represented in red and green, respectively (FDR < 0.05). See also Tables S1, S2. (C,D) Validation of RNA-seq data by comparing the transcriptional fold changes of 11 randomly selected genes determined by RNA-seq and an independent method (q-RT-PCR) for R. conorii- (C) and R. montanensis- (D) infected cells. Pearson analysis of correlation and respective significant test (two-tailed) were performed in GraphPad Prism. R. conorii-infected: r = 0.9208, N = 11, p < 0.0001 and R. montanensis-infected: r = 0.6437, N = 11, p < 0.05. Gene labeling: 1-B2M; 2-BTG2; 3-CD69; 4-EGR1; 5-EMC7; 6-G6PD; 7-IER3; 8-KLF10; 9-MTRNR2L6; 10-OTUD1; 11-PP1R15A. See also Table S3.
Figure 2Gene expression patterns stimulated by infection of THP-1 macrophages with R. conorii or R. montanensis reveal a more robust modulation by the pathogenic species. (A) Venn diagram depicting the number and distribution of specific and common DE genes in each experimental condition. UP means increased abundance, DOWN means decreased abundance, RC is R. conorii-infected cells and RM is R. montanensis-infected cells. See also Table S4. (B) Prediction of the activation/inhibition state of the top 30 canonical pathways in R. conorii-infected cells (R.c.) ranked by -log(p-value) and corresponding prediction states in R. montanensis-infected cells (R.m.) according to Ingenuity Pathway Analysis (IPA). Pink colored heatmap shows the top 30 canonical pathways for R. conorii-infected cells (R.c.) (ranked by -log(p-value) and the respective -log(p-value) for the correspondent pathway in R. montanensis-infected cells (R.m.). Red-green heatmap shows the prediction of activation (red)/inhibition (green) state (Z-score) in R. conorii-infected cells (R.c.) and R. montanensis-infected cells (R.m.). Pathways are considered to be inhibited or activated for Z-scores values < −2.0 or > 2.0, respectively. See also Table S4.
Categorization of the 58 DE genes commonly altered by the infection of either R. conorii or R. montanensis.
| Inflammatory response (GO:0006954) | 13 | 22.4 | 1.1 × 10−11 |
| Neutrophil chemotaxis (GO:0030593) | 8 | 13.8 | 8.0 × 10−11 |
| Cellular response to tumor necrosis factor (GO:0071356) | 8 | 13.8 | 3.0 × 10−9 |
| Chemokine-mediated signaling pathway (GO:0070098) | 7 | 12.1 | 8.1 × 10−9 |
| Cellular response to interleukin-1 (GO:0071347) | 7 | 12.1 | 8.1 × 10−9 |
| Immune response (GO:0006955) | 10 | 17.2 | 1.9 × 10−7 |
| Positive regulation of ERK1 and ERK2 cascade (GO:0070374) | 7 | 12.1 | 1.8 × 10−6 |
| Cellular response to lipopolysaccharide (GO:0071222) | 6 | 10.3 | 4.0 × 10−6 |
| Negative regulation of cell proliferation (GO:0008285) | 8 | 13.8 | 1.8 × 10−5 |
| Negative regulation of transcription from RNA polymerase II (GO:0000122) | 9 | 15.5 | 1.1 × 10−4 |
| G-protein coupled receptor signaling pathway (GO:0007186) | 9 | 15.5 | 5.2 × 10−4 |
| Positive regulation of transcription from RNA polymerase II promoter (GO:0045944) | 9 | 15.5 | 9.2 × 10−4 |
| Signal transduction (GO:0007165) | 8 | 13.8 | 1.1 x 10−2 |
| Extracellular region (GO:0005576) | 15 | 25.9 | 3.0 × 10−6 |
| Extracellular space (GO:0005615) | 12 | 20.7 | 8.4 × 10−5 |
| TNF signaling pathway (hsa04668) | 11 | 19.0 | 2.0 × 10−12 |
| Salmonella infection (hsa05132) | 8 | 13.8 | 1.5 × 10−8 |
| Toll-like receptor signaling pathway (hsa04620) | 8 | 13.8 | 8.5 × 10−8 |
| NF-kappa B signaling pathway (hsa04064) | 7 | 12.1 | 6.3 × 10−7 |
| Rheumatoid arthritis (hsa05323) | 7 | 12.1 | 6.7 × 10−7 |
| Legionellosis (hsa05134) | 6 | 10.3 | 1.4 × 10−6 |
| Chagas diseases (hsa05142) | 7 | 12.1 | 1.8 × 10−6 |
| Chemokine signaling pathway (hsa04062) | 8 | 13.8 | 3.9 × 10−6 |
| Cytokine-cytokine receptor interaction (hsa04060) | 8 | 13.8 | 1.6 × 10−5 |
| HTLV-I infection (hsa05166) | 6 | 10.3 | 2.3 x 10−3 |
Common DE genes are categorized using DAVID Bioinformatic Resources 6.8 according to GO terms: biological process and cellular component, and KEGG canonical pathways.
Categorization of the 409 DE genes uniquely altered in R. conorii-infected THP-1 macrophages.
| Positive regulation of transcription from RNA polymerase II promoter (GO:0045944) | 35 | 8.6 | 1.2 × 10−6 |
| Inflammatory response (GO:0006954) | 20 | 4.9 | 2.0 × 10−6 |
| Negative regulation of transcription from RNA polymerase II promoter (GO:0000122) | 25 | 6.1 | 9.0 × 10−5 |
| Response to lipopolysaccharide (GO:0032496) | 11 | 2.7 | 9.3 × 10−5 |
| Positive regulation of cell migration (GO:0030335) | 11 | 2.7 | 1.2 × 10−4 |
| Angiogenesis (GO:0001525) | 12 | 2.9 | 3.4 × 10−4 |
| Positive regulation of gene expression (GO:0010628) | 13 | 3.2 | 3.7 × 10−4 |
| Transcription from RNA polymerase II promoter (GO:0006366) | 19 | 4.7 | 3.9 × 10−4 |
| Cell adhesion (GO:0007155) | 17 | 4.2 | 8.9 × 10−4 |
| Negative regulation of apoptotic process (GO:0043066) | 16 | 3.9 | 2.2 × 10−3 |
| Apoptotic process (GO:0006915) | 18 | 4.4 | 3.0 × 10−3 |
| Positive regulation of transcription, DNA-templated (GO:0045893) | 16 | 3.9 | 6.8 × 10−3 |
| Immune response (GO:0006955) | 13 | 3.2 | 1.7 × 10−2 |
| Negative regulation of cell proliferation (GO:0008285) | 12 | 2.9 | 2.6 × 10−2 |
| Cell proliferation (GO:0008283) | 11 | 2.7 | 3.6 × 10−2 |
| Innate immune response (GO:0045087) | 11 | 2.7 | 8.7 × 10−2 |
| Integral component of plasma membrane (GO:0005887) | 34 | 8.3 | 1.7 × 10−3 |
| Extracellular space (GO:0005615) | 31 | 7.6 | 3.2 × 10−3 |
| Extracellular exosome (GO:0070062) | 53 | 13.0 | 1.2 × 10−2 |
| Extracellular region (GO:0005576) | 32 | 7.8 | 3.1 × 10−2 |
| Nucleus (GO:0005634) | 88 | 21.5 | 3.8 × 10−2 |
| Transcriptional misregulation in cancer (hsa05202) | 12 | 2.9 | 5.2 × 10−5 |
| Pertussis (hsa05133) | 6 | 1.5 | 5.9 × 10−3 |
| MAPK signaling pathway (hsa04010) | 11 | 2.7 | 5.9 × 10−3 |
| Osteoclast differentiation (hsa04380) | 8 | 2.0 | 4.1 × 10−3 |
| HTLV-I infection (hsa05166) | 9 | 2.2 | 4.4 × 10−2 |
| TNF signaling pathway (hsa04668) | 6 | 1.5 | 2.4 × 10−2 |
| NF-kappa B signaling pathway (hsa04064) | 7 | 1.7 | 2.2 × 10−2 |
| FoxO signaling pathway (hsa04068) | 7 | 1.7 | 1.7 × 10−2 |
| Viral carcinogenesis (hsa05203) | 9 | 2.2 | 1.4 × 10−2 |
| microRNAs in cancer (hsa05206) | 11 | 2.7 | 1.3 × 10−2 |
R. conorii-specific DE genes are categorized using DAVID Bioinformatic Resources 6.8 according to GO terms: biological process and cellular component, and KEGG canonical pathways.
Figure 3Rickettsia conorii and R. montanensis differentially modulate innate immune responses during THP-1 macrophage infection. Combined list of the individual DE genes (and respective log2 fold change values) categorized with the GO term inflammatory response (GO:0006954) and KEGG pathways: TLR signaling pathway (hsa04620), NF-κB signaling pathway (hsa04064), and TNF signaling pathway (hsa04668). DE genes in THP-1 macrophages infected with R. conorii are shown in black bars and in R. montanensis are shown in blue. The absence of bar means that the fold change of that gene for the respective experimental condition was not considered statistically significant. See also Table S6.
Predicted contribution of DE genes in R. conorii- and R. montanensis-THP-1 macrophages for inflammatory response based on “Diseases and Functions” category by IPA.
| Atypical chemokine receptor 3(ACKR3) | 0.81 | ||
| ADGRE5 | Adhesion G protein-coupled receptor E5(ADGRE5) | Affected | −0.66 |
| Angiotensinogen(AGT) | −0.57 | ||
| Activating transcription factor 3(ATF3) | 3.08 | ||
| C-C motif chemokine ligand 20(CCL20) | 4.57 | ||
| C-C motif chemokine ligand 3(CCL3) | 5.55 | ||
| CCL3L3 | C-C motif chemokine ligand 3 like 3(CCL3L3) | Affected | 7.05 |
| C-C motif chemokine receptor 1(CCR1) | −0.56 | ||
| CD14 molecule(CD14) | −0.86 | ||
| CD69 molecule(CD69) | 3.71 | ||
| CDO1 | Cysteine dioxygenase type 1(CDO1) | Affected | −1.82 |
| Cathepsin G(CTSG) | −0.69 | ||
| C-X-C motif chemokine ligand 1(CXCL1) | 5.59 | ||
| C-X-C motif chemokine ligand 3(CXCL3) | 5.55 | ||
| C-X-C motif chemokine ligand 8(CXCL8) | 4.24 | ||
| Endothelin 1(EDN1) | 2.15 | ||
| Elastase, neutrophil expressed(ELANE) | −0.71 | ||
| Endoglin(ENG) | −0.75 | ||
| FOS | Fos proto-oncogene, AP-1 transcription factor subunit(FOS) | Affected | 1.21 |
| Intercellular adhesion molecule 1(ICAM1) | 1.63 | ||
| Interleukin 1 alpha(IL1A) | 5.59 | ||
| Interleukin 1 beta(IL1B) | 2.98 | ||
| Galectin 3 binding protein(LGALS3BP) | −0.61 | ||
| Lysophosphatidic acid receptor 2(LPAR2) | −0.89 | ||
| BCL2 family apoptosis regulator(MCL1) | 0.78 | ||
| microRNA 223(MIR223) | −0.89 | ||
| Nuclear factor, erythroid 2 like 2(NFE2L2) | 1.28 | ||
| NFIL3 | Nuclear factor, interleukin 3 regulated(NFIL3) | Affected | 0.47 |
| NFKB inhibitor alpha(NFKBIA) | 5.29 | ||
| NLR family pyrin domain containing 3(NLRP3) | 1.14 | ||
| Notch 1(NOTCH1) | −0.70 | ||
| OSM | Oncostatin M(OSM) | Affected | 3.99 |
| PDGFB | Platelet derived growth factor subunit B(PDGFB) | Affected | 3.10 |
| Plasminogen activator, urokinase(PLAU) | 1.45 | ||
| Proteinase 3(PRTN3) | −0.73 | ||
| prostaglandin E receptor 4(PTGER4) | 1.55 | ||
| Prostaglandin-endoperoxide synthase 2(PTGS2) | 4.86 | ||
| PTX3 | Pentraxin 3(PTX3) | Affected | 1.75 |
| Regulator of G-protein signaling 1(RGS1) | 1.05 | ||
| RIPK2 | Receptor interacting serine/threonine kinase 2(RIPK2) | Affected | 1.32 |
| Scavenger receptor class B member 1(SCARB1) | −0.59 | ||
| Secretogranin II(SCG2) | −0.99 | ||
| SDC4 | Syndecan 4(SDC4) | Affected | 0.78 |
| SMAD family member 7(SMAD7) | 0.85 | ||
| Suppressor of cytokine signaling 3(SOCS3) | 4.89 | ||
| TICAM1 | Toll like receptor adaptor molecule 1(TICAM1) | Affected | 0.53 |
| Tumor necrosis factor(TNF) | 7.93 | ||
| TUBB2A | Tubulin beta 2A class IIa(TUBB2A) | Affected | 1.44 |
| ZFP36 | ZFP36 ring finger protein(ZFP36) | Affected | 2.76 |
| Activating transcription factor 3(ATF3) | 1.34 | ||
| CCL20 | C-C motif chemokine ligand 20(CCL20) | Activation | 2.97 |
| C-C motif chemokine ligand 3(CCL3) | 3.78 | ||
| CCL3L3 | C-C motif chemokine ligand 3 like 3(CCL3L3) | Affected | 5.08 |
| CD69 molecule(CD69) | 2.20 | ||
| C-X-C motif chemokine ligand 1(CXCL1) | 3.84 | ||
| C-X-C motif chemokine ligand 3(CXCL3) | 3.35 | ||
| C-X-C motif chemokine ligand 8(CXCL8) | 2.95 | ||
| Endothelin 1(EDN1) | 1.62 | ||
| Interleukin 1 beta(IL1B) | 1.41 | ||
| NFKB inhibitor alpha(NFKBIA) | 3.16 | ||
| Prostaglandin-endoperoxide synthase 2(PTGS2) | 2.74 | ||
| Tumor necrosis factor(TNF) | 5.34 | ||
| TNFSF11 | Tumor necrosis factor superfamily member 11(TNFSF11) | Affected | 2.12 |
| ZFP36 | ZFP36 ring finger protein(ZFP36) | Affected | 0.76 |
The software predicted activation/inhibition Z-scores of −0.092 (p-value of 5.29 × 10.
Figure 4Rickettsia conorii switches macrophage immune responses into a hyporesponsive state. Quantification of TNFα concentration in the culture media of uninfected (white), R. conorii- (black) and R. montanensis-infected (blue) THP-1 macrophages upon stimulation with E. coli O26:B6 LPS. Results are shown as mean ± SD and differences were considered non-significant (ns) at P > 0.05 or significant at **P ≤ 0.01, ***P ≤ 0.001.
Figure 5Rickettsia species differentially modulate the expression of several host apoptotic genes early in infection of THP-1 macrophages. Log2 fold change values of DE genes categorized with GO term “negative regulation of apoptotic process” (GO:0043066) in R. conorii- (black) and R. montanensis-infected (blue) cells. Absence of bar means that the fold change of that gene for the respective experimental condition was not considered statistically significant. See also Table S9.
Predicted contribution of DE genes in R. conorii- and R. montanensis-THP-1 macrophages for cell survival based on “Diseases and Functions” category by IPA.
| ATP binding cassette subfamily B member 6 (Langereis blood group)(ABCB6) | −0.55 | ||
| Atypical chemokine receptor 3(ACKR3) | 0.81 | ||
| Activating transcription factor 3(ATF3) | 3.08 | ||
| BCL2 related protein A1(BCL2A1) | 1.2 | ||
| B-cell CLL/lymphoma 3(BCL3) | 1.87 | ||
| BCL6 | B-cell CLL/lymphoma 6(BCL6) | Affected | 1.1 |
| BTG anti-proliferation factor 2(BTG2) | 2.97 | ||
| C-C motif chemokine ligand 3(CCL3) | 5.55 | ||
| CCR1 | C-C motif chemokine receptor 1(CCR1) | Affected | −0.56 |
| Cyclin dependent kinase inhibitor 1A(CDKN1A) | 0.67 | ||
| CCAAT/enhancer binding protein delta(CEBPD) | 0.62 | ||
| Connective tissue growth factor(CTGF) | 2.59 | ||
| C-X-C motif chemokine ligand 1(CXCL1) | 5.59 | ||
| C-X-C motif chemokine ligand 3(CXCL3) | 5.55 | ||
| C-X-C motif chemokine ligand 8(CXCL8) | 4.24 | ||
| Dual specificity phosphatase 1(DUSP1) | 4.68 | ||
| Dual specificity phosphatase 10(DUSP10) | 0.77 | ||
| Dual specificity phosphatase 5(DUSP5) | 0.96 | ||
| Extracellular matrix protein 1(ECM1) | −0.74 | ||
| Endothelin 1(EDN1) | 2.15 | ||
| Elastase, neutrophil expressed(ELANE) | −0.71 | ||
| Endoglin(ENG) | −0.75 | ||
| EPHB2 | EPH receptor B2(EPHB2) | Affected | −0.77 |
| ETS proto-oncogene 2, transcription factor(ETS2) | 1.07 | ||
| Fos proto-oncogene, AP-1 transcription factor subunit(FOS) | 1.21 | ||
| FOS like 1, AP-1 transcription factor subunit(FOSL1) | 1.01 | ||
| Ferritin heavy chain 1(FTH1) | 1.04 | ||
| Intercellular adhesion molecule 1(ICAM1) | 1.63 | ||
| Immediate early response 3(IER3) | 3.09 | ||
| Interleukin 1 alpha(IL1A) | 5.59 | ||
| Interleukin 1 beta(IL1B) | 2.98 | ||
| JUN proto-oncogene, AP-1 transcription factor subunit(JUN) | 3.14 | ||
| Lysine demethylase 6B(KDM6B) | 2.17 | ||
| Kruppel like factor 2(KLF2) | 2.5 | ||
| Kruppel like factor 6(KLF6) | 1.68 | ||
| Galectin 3 binding protein(LGALS3BP) | −0.61 | ||
| Lysophosphatidic acid receptor 2(LPAR2) | −0.89 | ||
| BCL2 family apoptosis regulator(MCL1) | 0.78 | ||
| microRNA 137(MIR137) | 2.13 | ||
| microRNA 223(MIR223) | −0.89 | ||
| Mitochondrial rRNA methyltransferase 1(MRM1) | −0.71 | ||
| v-myc avian myelocytomatosis viral oncogene homolog(MYC) | 0.71 | ||
| Nicotinamide phosphoribosyltransferase(NAMPT) | 1.25 | ||
| Nuclear factor, erythroid 2 like 2(NFE2L2) | 1.28 | ||
| Nuclear factor, interleukin 3 regulated(NFIL3) | 0.47 | ||
| Nuclear factor kappa B subunit 2(NFKB2) | 1.1 | ||
| NFKB inhibitor alpha(NFKBIA) | 5.29 | ||
| Notch 1(NOTCH1) | −0.7 | ||
| Nucleoporin 210(NUP210) | −0.59 | ||
| Oncostatin M(OSM) | 3.99 | ||
| PDGFB | Platelet derived growth factor subunit B(PDGFB) | Affected | 3.1 |
| PHB2 | prohibitin 2(PHB2) | Affected | −0.67 |
| Pim-3 proto-oncogene, serine/threonine kinase(PIM3) | 2.06 | ||
| Plasminogen activator, urokinase(PLAU) | 1.45 | ||
| Phorbol-12-myristate-13-acetate-induced protein 1(PMAIP1) | 1.02 | ||
| Prostaglandin-endoperoxide synthase 2(PTGS2) | 4.86 | ||
| REL proto-oncogene, NF-kB subunit(REL) | 0.66 | ||
| Ret proto-oncogene(RET) | −0.6 | ||
| Receptor interacting serine/threonine kinase 2(RIPK2) | 1.32 | ||
| Spermidine/spermine N1-acetyltransferase 1(SAT1) | 1.5 | ||
| Serum/glucocorticoid regulated kinase 1(SGK1) | 0.99 | ||
| Snail family transcriptional repressor 1(SNAI1) | 2.75 | ||
| SUPPRESSOR of cytokine signaling 3(SOCS3) | 4.89 | ||
| superoxide dismutase 2, mitochondrial(SOD2) | 3.25 | ||
| Toll like receptor adaptor molecule 1(TICAM1) | 0.53 | ||
| TIMP metallopeptidase inhibitor 1(TIMP1) | −0.61 | ||
| TIMP metallopeptidase inhibitor 3(TIMP3) | −0.63 | ||
| Tumor necrosis factor(TNF) | 7.93 | ||
| TNF alpha induced protein 3(TNFAIP3) | 3.68 | ||
| TNF alpha induced protein 8(TNFAIP8) | 0.86 | ||
| Tumor necrosis factor superfamily member 9(TNFSF9) | 1.25 | ||
| Tubulin gamma complex associated protein 6(TUBGCP6) | −0.53 | ||
| ZFP36 ring finger protein(ZFP36) | 2.76 | ||
| Activating transcription factor 3(ATF3) | 1.34 | ||
| BTG anti-proliferation factor 2(BTG2) | 1.07 | ||
| C-C motif chemokine ligand 3(CCL3) | 3.78 | ||
| Connective tissue growth factor(CTGF) | 1.21 | ||
| C-X-C motif chemokine ligand 1(CXCL1) | 3.84 | ||
| C-X-C motif chemokine ligand 3(CXCL3) | 3.35 | ||
| C-X-C motif chemokine ligand 8(CXCL8) | 2.95 | ||
| Dual specificity phosphatase 1(DUSP1) | 2.37 | ||
| Endothelin 1(EDN1) | 1.62 | ||
| Immediate early response 3(IER3) | 1.76 | ||
| Interleukin 1 beta(IL1B) | 1.41 | ||
| Jun proto-oncogene, AP-1 transcription factor subunit(JUN) | 1.35 | ||
| Kruppel like factor 5(KLF5) | 3.65 | ||
| NFKB inhibitor alpha(NFKBIA) | 3.16 | ||
| Prostaglandin-endoperoxide synthase 2(PTGS2) | 2.74 | ||
| Solute carrier family 40 member 1(SLC40A1) | −1.92 | ||
| Tumor necrosis factor(TNF) | 5.34 | ||
| TNF alpha induced protein 3(TNFAIP3) | 2.08 | ||
| Tumor necrosis factor superfamily member 11(TNFSF11) | 2.12 | ||
| ZFP36 ring finger protein(ZFP36) | 0.76 | ||
The software predicted activation/inhibition Z-scores of 3.661 (p-value of 1.41 × 10.
Figure 6Rickettsia conorii modulates host cell apoptosis during infection. (A) Percentage of cleaved PARP-positive cells, a marker of intrinsic apoptosis, over the course of infection of THP-1 macrophages with R. conorii. Results are shown as the mean ± SD and differences were considered non-significant (ns) at P > 0.05 or significant at *P < 0.05. (B) Immunofluorescence microscopy of uninfected cells and THP-1 macrophages infected with R. conorii at 1, 3, and 5 days post-infection. Cells were stained with DAPI (blue) to identify host nuclei, mouse anti-Rickettsia antibody (5C7.31) followed by anti-mouse Alexa Fluor 594 (red) to identify R. conorii and rabbit anti-cleaved poly(ADP-ribose) polymerase (PARP) followed by anti-rabbit Alexa Fluor 488 (green) to identify cleaved PARP-positive cells. Scale bar = 10 μm.
Figure 7Rickettsia conorii inhibits staurosporine-induced death of THP-1 macrophages at 5 days post-infection. (A) Uninfected and R. conorii-infected THP-1 macrophages at 1, 3, and 5 days post-infection were treated with staurosporine (750 nM) for 4 h. The percentage of cleaved PARP-positive cells in each experimental condition is shown as the mean ± SD and differences were considered ns (non-significant) at P > 0.05 or significant at *P < 0.05. (B) Immunofluorescence microscopy of uninfected cells and THP-1 macrophages infected with R. conorii at 1, 3, and 5 days post-infection upon challenge with staurosporine (750 nM) for 4 h. Cells were stained with DAPI (blue) to identify host nuclei, mouse anti-Rickettsia antibody (5C7.31) followed by anti-mouse Alexa Fluor 594 (red) to identify R. conorii and rabbit anti-cleaved poly(ADP-ribose) polymerase (PARP) followed by anti-rabbit Alexa Fluor 488 (green) to identify cleaved PARP-positive cells. Scale bar = 10 μm.
Figure 8Rickettsia species differentially modulate the expression of several gene expression regulators early in infection of THP-1 macrophages. (A) Distribution of DE non-coding RNAs according to their category in R. conorii- (black) and R. montanensis- (blue) infected cells. scaRNAs (small Cajal body-specific RNAs), snoRNAs (small nucleolar RNAs), 5S-rRNAs (5S ribosomal RNAs), U-RNA (small nuclear RNAs), 7SL RNAs (signal recognition particle RNAs), 7SK RNAs (7SK small nuclear RNAs), lincRNAs (long intergenic noncoding RNAs), miRNAs (microRNAs). Number of genes for each orientation [increased abundance (UP) or decreased abundance (DOWN)] is represented in each bar. See Table S10 for details about individual transcripts. (B) STRING analysis of DE genes in R. conorii-infected cells categorized in the GO term “positive or negative regulators of transcription from RNA polymerase II promoter.” Nodes corresponding to DE genes categorized with transcriptional activator activity (GO:0001228) are in red and with transcriptional repressor activity (GO:0001227) are in blue. See also Table S11.
Predicted contribution of DE genes in R. conorii- and R. montanensis-THP-1 macrophages for transcription based on “Diseases and Functions” category by IPA.
| Angiotensinogen(AGT) | −0.57 | ||
| ATF3 | Activating transcription factor 3(ATF3) | Affected | 3.08 |
| B-cell CLL/lymphoma 3(BCL3) | 1.87 | ||
| B-cell CLL/lymphoma 6(BCL6) | 1.1 | ||
| Basic helix-loop-helix family member e40(BHLHE40) | 2.49 | ||
| BTG anti-proliferation factor 2(BTG2) | 2.97 | ||
| CCL3 | C-C motif chemokine ligand 3(CCL3) | Affected | 5.55 |
| C-C motif chemokine receptor 1(CCR1) | −0.56 | ||
| Cyclin dependent kinase inhibitor 1A(CDKN1A) | 0.67 | ||
| CEBPD | CCAAT/enhancer binding protein delta(CEBPD) | Affected | 0.62 |
| CITED2 | Cbp/p300 interacting transactivator with Glu/Asp rich Carboxy-terminal domain 2(CITED2) | Affected | 0.74 |
| cAMP responsive element binding protein 5(CREB5) | 2.65 | ||
| Cysteine and serine rich nuclear protein 1(CSRNP1) | 1.75 | ||
| C-X-C motif chemokine ligand 3(CXCL3) | 5.55 | ||
| E2F7 | E2F transcription factor 7(E2F7) | Affected | 0.78 |
| Extracellular matrix protein 1(ECM1) | −0.74 | ||
| EDN1 | Endothelin 1(EDN1) | Affected | 2.15 |
| Early growth response 1(EGR1) | 3.32 | ||
| Early growth response 2(EGR2) | 0.91 | ||
| Early growth response 4(EGR4) | 3.94 | ||
| Elastase, neutrophil expressed(ELANE) | −0.71 | ||
| ENG | endoglin(ENG) | Affected | −0.75 |
| ETS proto-oncogene 2, transcription factor(ETS2) | 1.07 | ||
| Fos proto-oncogene, AP-1 transcription factor subunit(FOS) | 1.21 | ||
| FosB proto-oncogene, AP-1 transcription factor subunit(FOSB) | 4.02 | ||
| FOS like 1, AP-1 transcription factor subunit(FOSL1) | 1.01 | ||
| H1 histone family member 0(H1F0) | 0.53 | ||
| ID1 | Inhibitor of DNA binding 1, HLH protein(ID1) | Activation | −1.23 |
| Immediate early response 2(IER2) | 1.54 | ||
| Immediate early response 5(IER5) | 1.37 | ||
| Interleukin 1 alpha(IL1A) | 5.59 | ||
| Interleukin 1 beta(IL1B) | 2.98 | ||
| Jun proto-oncogene, AP-1 transcription factor subunit(JUN) | 3.14 | ||
| Lysine demethylase 6B(KDM6B) | 2.17 | ||
| Kruppel like factor 2(KLF2) | 2.5 | ||
| Kruppel like factor 6(KLF6) | 1.68 | ||
| Kruppel like factor 10(KLF10) | 2.4 | ||
| LCP2 | Lymphocyte cytosolic protein 2(LCP2) | Affected | 0.65 |
| LPAR2 | Lysophosphatidic acid receptor 2(LPAR2) | Activation | −0.89 |
| MAF bZIP transcription factor F(MAFF) | 1.74 | ||
| MID1 interacting protein 1(MID1IP1) | 0.51 | ||
| microRNA 223(MIR223) | −0.89 | ||
| MSC | Musculin(MSC) | Affected | 0.89 |
| MAX dimerization protein 1(MXD1) | 0.81 | ||
| v-myc avian myelocytomatosis viral oncogene homolog(MYC) | 0.71 | ||
| Nicotinamide phosphoribosyltransferase(NAMPT) | 1.25 | ||
| Nuclear factor, erythroid 2 like 2(NFE2L2) | 1.28 | ||
| Nuclear factor, interleukin 3 regulated(NFIL3) | 0.47 | ||
| NFKB2 | Nuclear factor kappa B subunit 2(NFKB2) | Affected | 1.10 |
| NFKB inhibitor alpha(NFKBIA) | 5.29 | ||
| NFKBIZ | NFKB inhibitor zeta(NFKBIZ) | Affected | 4.53 |
| NOCT | Nocturnin(NOCT) | Affected | 1.66 |
| Notch 1(NOTCH1) | −0.70 | ||
| Oncostatin M(OSM) | 3.99 | ||
| Protocadherin 11 Y-linked(PCDH11Y) | −4.00 | ||
| PDGFB | Platelet derived growth factor subunit B(PDGFB) | Affected | 3.10 |
| Prohibitin 2(PHB2) | −0.67 | ||
| Polo like kinase 3(PLK3) | 1.14 | ||
| PR/SET domain 1(PRDM1) | 2.05 | ||
| Prostaglandin E receptor 4(PTGER4) | 1.55 | ||
| PTGES3 | Prostaglandin E synthase 3(PTGES3) | Affected | 0.59 |
| RB binding protein 8, endonuclease(RBBP8) | −2.55 | ||
| REL proto-oncogene, NF-kB subunit(REL) | 0.66 | ||
| Ret proto-oncogene(RET) | −0.60 | ||
| Ras homolog family member B(RHOB) | 1.31 | ||
| Receptor interacting serine/threonine kinase 2(RIPK2) | 1.32 | ||
| Serum/glucocorticoid regulated kinase 1(SGK1) | 0.99 | ||
| SMAD family member 1(SMAD1) | −1.75 | ||
| SMAD family member 7(SMAD7) | 0.85 | ||
| Snail family transcriptional repressor 1(SNAI1) | 2.75 | ||
| Suppressor of cytokine signaling 3(SOCS3) | 4.89 | ||
| SOD2 | Superoxide dismutase 2, mitochondrial(SOD2) | Affected | 3.25 |
| TIMP metallopeptidase inhibitor 1(TIMP1) | −0.61 | ||
| TIMP metallopeptidase inhibitor 3(TIMP3) | −0.63 | ||
| Tumor necrosis factor(TNF) | 7.93 | ||
| TNF receptor associated factor 1(TRAF1) | 1.44 | ||
| Zinc finger and BTB domain containing 5(ZBTB5) | 0.77 | ||
| Zinc finger CCCH-type containing 12A(ZC3H12A) | 2.39 | ||
| ZFP36 ring finger protein(ZFP36) | 2.76 | ||
| Zinc finger protein 536(ZNF536) | −0.73 | ||
| Zinc finger protein 692(ZNF692) | −0.59 | ||
| ATF3 | Activating transcription factor 3(ATF3) | Affected | 1.34 |
| BTG anti-proliferation factor 2(BTG2) | 1.07 | ||
| CCL3 | C-C motif chemokine ligand 3(CCL3) | Affected | 3.78 |
| C-X-C motif chemokine ligand 3(CXCL3) | 3.35 | ||
| EDN1 | Endothelin 1(EDN1) | Affected | 1.62 |
| Early growth response 1(EGR1) | 0.80 | ||
| Interleukin 1 beta(IL1B) | 1.41 | ||
| Jun proto-oncogene, AP-1 transcription factor subunit(JUN) | 1.35 | ||
| Kruppel like factor 5(KLF5) | 3.65 | ||
| Kruppel like factor 10(KLF10) | 0.85 | ||
| NFKB inhibitor alpha(NFKBIA) | 3.16 | ||
| NFKBIZ | NFKB inhibitor zeta(NFKBIZ) | Affected | 2.78 |
| Nuclear receptor subfamily 2 group F member 2(NR2F2) | 3.69 | ||
| RB binding protein 8, endonuclease(RBBP8) | −2.57 | ||
| Tumor necrosis factor(TNF) | 5.34 | ||
| Tumor necrosis factor superfamily member 11(TNFSF11) | 2.12 | ||
| Zinc finger CCCH-type containing 12A(ZC3H12A) | 1.06 | ||
| ZFP36 ring finger protein(ZFP36) | 0.76 | ||
The software predicted activation/inhibition Z-scores of 2.428 (p-value of 5.27 x 10.